Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ticket reseller Stubhub eyes $9bn IPO

(Sharecast News) - Concert ticket resale platform StubHub is targeting a valuation of up to $9.2bn in a planned US listing, the company said on Monday. The firm is looking to raise up to $851m via the sale of around 34 million shares priced between $22 - $25 each as it looks to cash in on big money events.

StubHub's ticketing marketplace allows fans to purchase tickets for live events, although it has come under fire for failing to stop touts from advertising large numbers of tickets at inflated markups after they used automated bots to buy them from platforms such as Ticketmaster.

The UK government is considering a ban on for-profit ticket resale in an effort to protect consumers.

StubHub was co-founded in 2000 by Jeff Fluhr and current chief executive Eric Baker, who had initially left the firm - and launched viagogo, a rival ticket reseller - in Europe in 2006.

The company was looking at an IPO with a $16.5bn in April 2024 but shelved the plan due to "choppy" market conditions at least until the autumn of the last year. In March listing plans were again announced then put on hold in the wake of US Donald Trump's global tariff war.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.